Literature DB >> 27603301

Association between IL-33 Gene Polymorphisms (rs1929992, rs7044343) and Systemic Lupus Erythematosus in a Chinese Han Population.

Wangdong Xu1,2, Yi Liu1, Dongqing Ye2.   

Abstract

OBJECTIVE: Interleukin-33 (IL-33) is a member of the IL-1 family, and previous studies found the single-nucleotide polymorphisms (SNPs) in the IL-33 gene was related to susceptibility to autoimmune diseases, including rheumatoid arthritis, ankylosing spondylitis and Behcet's disease. To date, no study has discussed the potential association between IL-33 gene polymorphisms and systemic lupus erythematosus (SLE).
METHODS: We conducted a case-control study including 371 SLE patients and 408 healthy controls to investigate the correlation between the SNPs of IL-33 gene (rs1929992, rs7044343) and SLE in a Chinese Han population.
RESULTS: There was significantly lower expression of allele G for rs1929992 in SLE patients than that in controls (G versus A, P = 0.012, OR = 1.310, 95% CI: 1.060-1.624 after adjustment with sex). Similarly, genotype GG was associated with the susceptibility to SLE as compared with the AA genotype (P = 0.017, OR = 1.714, 95% CI: 1.101-2.669 after adjustment with sex). We also found statistical significance in the dominant model (GG+GA versus AA, P = 0.017, OR = 1.481, 95% CI: 1.074-2.044 after adjustment with sex). However, we found no strong evidence for the association of IL-33 rs7044343 polymorphism with SLE. Moreover, association studies were performed on the relationship between the IL-33 gene polymorphisms and lupus nephritis as well as nine clinical features of SLE, but there was no significant association regarding the distribution of allele and genotype frequencies between SLE patients positive and negative for the presence of sub-phenotypes.
CONCLUSION: Our findings indicate that IL-33 rs1929992 polymorphism may be a potential biomarker for susceptibility to SLE.

Entities:  

Keywords:  Interleukin-33; single-nucleotide polymorphism; systemic lupus erythematosus

Mesh:

Substances:

Year:  2016        PMID: 27603301     DOI: 10.1080/08820139.2016.1193868

Source DB:  PubMed          Journal:  Immunol Invest        ISSN: 0882-0139            Impact factor:   3.657


  10 in total

1.  Generation and Characterization of Torudokimab (LY3375880): A Monoclonal Antibody That Neutralizes Interleukin-33.

Authors:  Angela J Okragly; Katie Brannon Corwin; Marikka Elia; Dongmei He; Oliver Schroeder; Qing Zhang; Tatiyana Shiyanova; Stuart Bright; Sarah B Dicker; Lukasz Chlewicki; Stephanie M E Truhlar; Julian Davies; Chetan N Patel; Robert J Benschop
Journal:  J Inflamm Res       Date:  2021-08-11

2.  Interleukin-33 Contributes Toward Loss of Tolerance by Promoting B-Cell-Activating Factor of the Tumor-Necrosis-Factor Family (BAFF)-Dependent Autoantibody Production.

Authors:  William A Rose; Angela J Okragly; Ningjie N Hu; Montanea R Daniels; Andrea P Martin; Yi Ting Koh; Kristine Kikly; Robert J Benschop
Journal:  Front Immunol       Date:  2018-12-06       Impact factor: 7.561

3.  Interaction between IL-33 Gene Polymorphisms and Current Smoking with Susceptibility to Systemic Lupus Erythematosus.

Authors:  Xiaohua Zhu; Lin Xie; Haihong Qin; Jun Liang; Yongsheng Yang; Jinhua Xu; Tiejun Zhang
Journal:  J Immunol Res       Date:  2019-03-11       Impact factor: 4.818

4.  Investigation Trp64Arg polymorphism of the beta 3-adrenergic receptor gene in nonobese women with polycystic ovarian syndrome.

Authors:  Farideh Zafari Zangeneh; Maryam Sarmast Shoushtari; Sahar Shojaee; Elahe Aboutorabi
Journal:  Int J Reprod Biomed       Date:  2020-03-29

5.  Early Treatment of Interleukin-33 can Attenuate Lupus Development in Young NZB/W F1 Mice.

Authors:  Fatin Nurizzati Mohd Jaya; Zhongyi Liu; Godfrey Chi-Fung Chan
Journal:  Cells       Date:  2020-11-10       Impact factor: 6.600

6.  CD44, IL-33, and ST2 Gene Polymorphisms on Hepatocellular Carcinoma Susceptibility in the Chinese Population.

Authors:  Xiaolan Pan; Meiqin Li; Lei Huang; Dan Mo; Yihua Liang; Zhaodong Huang; Bo Zhu; Min Fang
Journal:  Biomed Res Int       Date:  2020-09-29       Impact factor: 3.411

7.  Interleukin (IL)-1 family cytokines could differentiate primary immune thrombocytopenia from systemic lupus erythematosus-associated thrombocytopenia.

Authors:  Yanxia Zhan; Luya Cheng; Boting Wu; Lili Ji; Pu Chen; Feng Li; Jingjing Cao; Yang Ke; Ling Yuan; Zhihui Min; Lihua Sun; Hao Chen; Fanli Hua; Yunfeng Cheng
Journal:  Ann Transl Med       Date:  2021-02

8.  NETs decorated with bioactive IL-33 infiltrate inflamed tissues and induce IFN-α production in patients with SLE.

Authors:  Spiros Georgakis; Katerina Gkirtzimanaki; Garyfalia Papadaki; Hariklia Gakiopoulou; Elias Drakos; Maija-Leena Eloranta; Manousos Makridakis; Georgia Kontostathi; Jerome Zoidakis; Eirini Baira; Lars Rönnblom; Dimitrios T Boumpas; Prodromos Sidiropoulos; Panayotis Verginis; George Bertsias
Journal:  JCI Insight       Date:  2021-11-08

Review 9.  IL-33/IL-31 Axis: A Potential Inflammatory Pathway.

Authors:  Eleonora Di Salvo; Elvira Ventura-Spagnolo; Marco Casciaro; Michele Navarra; Sebastiano Gangemi
Journal:  Mediators Inflamm       Date:  2018-03-11       Impact factor: 4.711

Review 10.  Involvement of IL-33 in the Pathophysiology of Systemic Lupus Erythematosus: Review.

Authors:  Julie Sarrand; Muhammad Soyfoo
Journal:  Int J Mol Sci       Date:  2022-03-15       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.